Epigenetic Silencing of ZNF471 Contributes to Osimertinib Resistance in Lung Adenocarcinoma: β-Hydroxybutyrate Associates with ZNF471 Re-Expression and Reduced Resistance-Associated Phenotypes
Oncology Research · 2026
DOI: 10.32604/or.2026.087712 ↗Kurz gefasst
Fachartikel in der Zeitschrift Oncology Research, 2026. Verfasst von Dade Feng und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Yueyang People's Hospital of Hunan Normal University, Yueyang, China. Hauptthemen laut MEDLINE: Drug Resistance, Neoplasm, Adenocarcinoma of Lung, Lung Neoplasms, Epigenesis, Genetic. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, Yueyang People's Hospital of Hunan Normal University, Yueyang, China.
- School of Basic Medical Sciences, Hunan Normal University Health Science Center, Hunan Normal University, Changsha, China.
- Department of Orthopedics, Yueyang People's Hospital of Hunan Normal University, Yueyang, China.
- Department of Science and Education, Yueyang People's Hospital of Hunan Normal University, Yueyang, China.
Zitieren
APA
Feng, D., Yan, H., Ni, Q., Peng, Z., Xu, X., Liang, Y., & Liu, C. (2026). Epigenetic Silencing of ZNF471 Contributes to Osimertinib Resistance in Lung Adenocarcinoma: β-Hydroxybutyrate Associates with ZNF471 Re-Expression and Reduced Resistance-Associated Phenotypes. Oncology Research. https://doi.org/10.32604/or.2026.087712
Vancouver
Feng D, Yan H, Ni Q, Peng Z, Xu X, Liang Y, et al. Epigenetic Silencing of ZNF471 Contributes to Osimertinib Resistance in Lung Adenocarcinoma: β-Hydroxybutyrate Associates with ZNF471 Re-Expression and Reduced Resistance-Associated Phenotypes. Oncology Research. 2026. doi:10.32604/or.2026.087712
BibTeX
@article{Feng2026,
author = {Feng, Dade and Yan, Huiting and Ni, Qian and Peng, Zirui and Xu, Xiong and Liang, Yanfang and Liu, Chongmei},
title = {Epigenetic Silencing of ZNF471 Contributes to Osimertinib Resistance in Lung Adenocarcinoma: β-Hydroxybutyrate Associates with ZNF471 Re-Expression and Reduced Resistance-Associated Phenotypes},
journal = {Oncology Research},
year = {2026},
doi = {10.32604/or.2026.087712}
}
EUVIMED